$200.00
Melanotan 1, also known as Afamelanotide, is a synthetic analog of alpha-melanocyte–stimulating hormone (α-MSH) studied for its selective interaction with melanocortin-1 receptors (MC1R). In controlled research environments, Melanotan 1 is evaluated for its influence on melanogenesis signaling, pigmentation dynamics, and photoprotective pathway modeling.
Compared to broader melanocortin agonists, Melanotan 1 demonstrates greater selectivity for MC1R, making it a focused compound for pigmentation-focused research frameworks.
Research Name: Melanotan 1
Alias: MT-1, Afamelanotide
Category: Selective melanocortin receptor agonist
Primary Research Focus: Melanogenesis modeling, pigmentation signaling, UV-response analysis
Format: Lyophilized powder
Upon reconstitution with an appropriate volume of bacteriostatic water, final concentration will vary depending on total diluent added. Researchers calculate concentration using the standard formula:
Total mg in vial ÷ Total mL added = mg per mL
For U-100 insulin syringes:
1 mL = 100 units
Units required are determined by dividing the desired mg amount by the final mg/mL concentration.
Melanotan 1 is studied for its potential influence on:
MC1R Activation
Melanocyte receptor signaling
Melanin production pathways
Pigment-regulation modeling
Pigmentation & Photoprotection Studies
UV-response pathway evaluation
Skin-tone adaptation analysis
Oxidative stress response in dermal models
Melanocortin Signaling Dynamics
α-MSH receptor interaction frameworks
Downstream cAMP pathway activation
Its selective MC1R activity differentiates it from broader melanocortin agonists that engage multiple receptor subtypes.
Within structured research environments, investigators may observe:
Dose-dependent variables
Gradual pigmentation response
Flushing
Mild nausea
Pigmentation-related observations
Freckle or mole darkening
Skin-tone shifts within controlled models
Less frequent observations
Headache
Injection-site irritation
Temporary fatigue
Monitoring is typically focused on pigmentation trends and melanocortin pathway response markers.
Administration Frequency: Varies by study design (commonly titrated protocols)
Common Study Duration: 4–8 weeks
Titration Strategy: Gradual incremental increases to evaluate receptor response
Researchers may exercise caution when combining Melanotan 1 with other melanocortin-modulating agents to prevent overlapping receptor activation effects.
Store lyophilized vial in a cool, dry environment.
Refrigerate after reconstitution.
Maintain sterile laboratory handling procedures at all times.
